Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03975114
Recruitment Status : Recruiting
First Posted : June 5, 2019
Last Update Posted : June 5, 2019
Sponsor:
Collaborators:
University of Campania "Luigi Vanvitelli"
AstraZeneca
Information provided by (Responsible Party):
National Cancer Institute, Naples

Brief Summary:

This is a randomized phase 2 trial aiming to assess the early efficacy of two experimental treatment sequences.

Three arms are planned; (i) standard chemotherapy followed at progression by single agent immunotherapy with durvalumab (CT), (ii) experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy, (iii) experimental combination immunotherapy with durvalumab+tremelimumab followed at progression by chemotherapy.

The the two experimental strategies will be compared with the standard strategy in terms of 12-month overall survival, time considered informative for the type of treatment and disease


Condition or disease Intervention/treatment Phase
Carcinoma, Non-Small-Cell Lung Drug: Chemotherapy Drug: Durvalumab Drug: Tremelimumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 460 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Comparative Randomized Phase 2 Design
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase 2 Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)
Actual Study Start Date : December 20, 2018
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : June 30, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Durvalumab

Arm Intervention/treatment
Active Comparator: Chemo first
Standard chemotherapy followed at progression by durvalumab
Drug: Chemotherapy
Any approved first line chemotherapy regimen at Investigators' choice

Drug: Durvalumab
Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal

Experimental: Immuno Monotherapy first
Experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy
Drug: Chemotherapy
Any approved first line chemotherapy regimen at Investigators' choice

Drug: Durvalumab
Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal

Experimental: Immuno Combination Therapy first
experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy
Drug: Chemotherapy
Any approved first line chemotherapy regimen at Investigators' choice

Drug: Durvalumab
Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal

Drug: Tremelimumab
Tremelimumab 75 mg iv Q4w for 4 administrations (4 months)




Primary Outcome Measures :
  1. 12-month overall survival [ Time Frame: 12 months ]
    12-month overall survival is defined as the Kaplan-Meier (K-M) survival probability at 12 months after randomization (Chen 2015).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   70 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female >= 70 years of age.
  2. Histological documentation of primary squamous or non squamous non-small cell lung carcinoma.
  3. Availability of archived tumor tissue block or newly cut unstained slides for PD-L1 determination.
  4. Stage IV or IIIB disease with supraclavear metastatic nodes (according to TNM 7th edition).
  5. Clinical or radiologic evidence of disease (at least one measurable or non measurable lesion).
  6. ECOG performance status 0 to 1.
  7. Life expectancy > 3 months.
  8. Adequate renal and hepatic function, defined as:

    1. Total serum bilirubin ≤ 1.5 institutional ULN.
    2. AST and/or ALT ≤ 2.5 x ULN for the institution (or ≤ 5 x ULN if liver metastases are present)
    3. Serum creatinine ≤ 1.5 x ULN for the institution (or calculated creatinine clearance ≥ 40 mL/min/1.73 m2).
  9. Adequate bone marrow function, defined as:

    1. Haemoglobin <= 9.0 g/dL
    2. Absolute neutrophils count (ANC) >= 1.5 x 109/L (> 1500 per mm3)
    3. Platelet count <= 100 x 109/L(>100,000 per mm3).
  10. Written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.

Exclusion Criteria:

Cancer related

  1. Activating epidermal growth factor receptor mutation (exon19 deletion or exon 21 L858R mutation or other activating/sensitizing mutations).
  2. ALK or ROS1 positive (immunohistochemistry or FISH)
  3. Mixed small-cell lung cancer and NSCLC histology.

    Prior, current or planned treatment related

  4. Prior chemotherapy or any other medical treatment for advanced NSCLC (previous neoadjuvant or adjuvant chemotherapy is allowed if > 6 months previously).
  5. Prior exposure to immunomodulatory therapy, including, but not limited to, other anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies.
  6. Current or prior use of immunosuppressive medication within 14 days before the first dose of study treatment (intranasal and inhaled corticosteroids at physiological doses not exceeding 10 mg/day of prednisone or an equivalent corticosteroid are allowed).
  7. Any concurrent investigational product or other anticancer treatment.

    Prior or concomitant conditions or procedures related

  8. Active or prior documented autoimmune disease within the past 2 years (subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment within the past 2 years, are not excluded).
  9. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
  10. History of allogeneic organ transplant
  11. History of active primary immunodeficiency.
  12. Active infection, including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  13. Receipt of live attenuated vaccine within 30 days prior to the first dose of study drugs.
  14. Patients with previous malignancies (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer or surgically resected prostate cancer with normal PSA) are excluded only if the histological diagnosis of the current disease does not definitely support the pulmonary origin.
  15. Brain metastases or spinal cord compression, unless asymptomatic, previously treated, and stable off steroids and anti-convulsants for at least one month prior to study entry.
  16. Leptomeningeal carcinomatosis
  17. Clinically significant cardiovascular disease, including:

    1. Myocardial infarction or unstable angina pectoris within < 6 months prior to the first study treatment
    2. New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF)
    3. Uncontrolled hypertension
    4. Serious cardiac arrhythmia requiring medication (with the exception of atrial fibrillation or paroxysmal supraventricular tachycardia)
    5. Peripheral vascular disease > grade 3 (i.e. symptomatic and interfering with activities of daily living requiring repair or revision)
    6. Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Fredericia's Correction.
  18. Serious active infection requiring i.v. antibiotics at enrollment.
  19. Known hypersensitivity to any of the study drugs or excipients.
  20. Evidence of any other concomitant pathologies, physical examination or laboratory findings (including but not limited to active peptic ulcer disease or gastritis, active bleeding diatheses or psychiatric illness) or social situation that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment related complications.
  21. Radiotherapy treatment to the chest or to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study treatment (patients who have had radiotherapy ≥ 4 weeks prior to the first dose of study treatment, but who are still experiencing acute toxic effects of radiotherapy are also excluded).
  22. Major surgical procedure within 28 days prior to the first dose of study drugs.
  23. Male patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of study treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03975114


Contacts
Layout table for location contacts
Contact: Maria Carmela Piccirillo, MD +390815903615 m.piccirillo@istitutotumori.na.it
Contact: Francesco Perrone, MD, PhD +390815903571 f.perrone@istitutotumori.na.it

Locations
Layout table for location information
Italy
Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale Recruiting
Napoli, Italy, 80131
Contact: Alessandro Morabito, MD    +390815903637    a.morabito@istitutotumori.na.it   
Sponsors and Collaborators
National Cancer Institute, Naples
University of Campania "Luigi Vanvitelli"
AstraZeneca
Investigators
Layout table for investigator information
Study Chair: Francesco Perrone, MD, PhD Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale

Additional Information:
Layout table for additonal information
Responsible Party: National Cancer Institute, Naples
ClinicalTrials.gov Identifier: NCT03975114     History of Changes
Other Study ID Numbers: MILES-5
First Posted: June 5, 2019    Key Record Dates
Last Update Posted: June 5, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Data will be available at request

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by National Cancer Institute, Naples:
Eldelry
metastatic Non-Small-Cell Lung Cancer
Durvalumab
Immunotherapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Immunologic Factors
Antibodies, Monoclonal
Durvalumab
Tremelimumab
Physiological Effects of Drugs
Antineoplastic Agents, Immunological
Antineoplastic Agents